157 related articles for article (PubMed ID: 17482095)
1. Alpha-galactosidase A in vascular disease.
Bodary PF; Shayman JA; Eitzman DT
Trends Cardiovasc Med; 2007 May; 17(4):129-33. PubMed ID: 17482095
[TBL] [Abstract][Full Text] [Related]
2. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency.
Bodary PF; Shen Y; Vargas FB; Bi X; Ostenso KA; Gu S; Shayman JA; Eitzman DT
Circulation; 2005 Feb; 111(5):629-32. PubMed ID: 15668341
[TBL] [Abstract][Full Text] [Related]
3. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
[TBL] [Abstract][Full Text] [Related]
4. A novel small insertion mutation, C.1030_1031ins (T) in α-galactosidase A leads to renal variant fabry disease.
Choi JS; Kim CS; Park JW; Bae EH; Ma SK; Choi YD; Kim GH; Yoo HW; Kim SW
Ren Fail; 2012; 34(3):390-3. PubMed ID: 22260214
[TBL] [Abstract][Full Text] [Related]
5. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
6. Fabry disease.
Schiffmann R
Pharmacol Ther; 2009 Apr; 122(1):65-77. PubMed ID: 19318041
[TBL] [Abstract][Full Text] [Related]
7. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.
Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG
PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451
[TBL] [Abstract][Full Text] [Related]
8. Normal hearing in alpha-galactosidase A-deficient mice, the mouse model for Fabry disease.
Noben-Trauth K; Neely H; Brady RO
Hear Res; 2007 Dec; 234(1-2):10-4. PubMed ID: 17933476
[TBL] [Abstract][Full Text] [Related]
9. α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.
Kang JJ; Kaissarian NM; Desch KC; Kelly RJ; Shu L; Bodary PF; Shayman JA
Kidney Int; 2019 Jan; 95(1):149-159. PubMed ID: 30470436
[TBL] [Abstract][Full Text] [Related]
10. 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality.
Yam GH; Roth J; Zuber C
Biochem Biophys Res Commun; 2007 Aug; 360(2):375-80. PubMed ID: 17592721
[TBL] [Abstract][Full Text] [Related]
11. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
12. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
[TBL] [Abstract][Full Text] [Related]
13. Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse.
Park JL; Shu L; Shayman JA
Am J Physiol Heart Circ Physiol; 2009 Apr; 296(4):H1133-40. PubMed ID: 19202000
[TBL] [Abstract][Full Text] [Related]
14. Promoter dependence of plasmid-pluronics targeted alpha galactosidase A expression in skeletal muscle of Fabry mice.
Lavigne MD; Pohlschmidt M; Novo JF; Higgins B; Alakhov V; Lochmuller H; Sakuraba H; Goldspink G; MacDermot K; Górecki DC
Mol Ther; 2005 Nov; 12(5):985-90. PubMed ID: 15975851
[No Abstract] [Full Text] [Related]
15. An in vitro model of Fabry disease.
Shu L; Murphy HS; Cooling L; Shayman JA
J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease - Vascular manifestations.
Karetova D; Bultas J; Dostalova G; Palecek T; Kovarnik T; Golan L; Linhart A
Vasa; 2010 May; 39(2):123-31. PubMed ID: 20464667
[TBL] [Abstract][Full Text] [Related]
17. [Biochemical and pathological studies on a carrier of Fabry's disease manifesting bouts of pain in the extremities].
Katayama M; Kobayashi T; Ohnishi A; Goto I; Kuroiwa Y
Rinsho Shinkeigaku; 1984 Jun; 24(6):575-80. PubMed ID: 6094070
[No Abstract] [Full Text] [Related]
18. [Update on the treatment of Fabry's disease: pathophysiological concepts].
Politei JM
Rev Neurol; 2010 Nov; 51(9):561-70. PubMed ID: 20979036
[TBL] [Abstract][Full Text] [Related]
19. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
20. No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene.
Kobayashi M; Ohashi T; Fukuda T; Yanagisawa T; Inomata T; Nagaoka T; Kitagawa T; Eto Y; Ida H; Kusano E
Mol Genet Metab; 2012 Dec; 107(4):711-5. PubMed ID: 23146289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
